Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

NEXT STORY
CORRECTION — Assure Holdings Reports First Quarter 2021 Financial Results
PREV STORY
PM360 Announces Winners of The Seventh Annual ELITE Awards
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

NEXT STORY
CORRECTION — Assure Holdings Reports First Quarter 2021 Financial Results
PREV STORY
PM360 Announces Winners of The Seventh Annual ELITE Awards
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of NLA101 in Patients with AML

SEATTLE, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a clinical stage ...

author_avatar
NASDAQ Market News

argenx reports third quarter 2017 financial results and provides business update

October 26, 2017 Breda, the Netherlands / Ghent, Belgium argenx (Euronext Brussels & Nasdaq: ...

author_avatar
NASDAQ Market News

VBL Therapeutics to Report Fiscal 2017 Results on March 15

TEL AVIV, Israel, March 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage ...

author_avatar
NASDAQ Market News